Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Nationwide safety program associated with 65% reduction in hospital-onset MRSA bloodstream infections (opens in a new tab)

medicalxpress.com · 2026-09-14

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

One claim goes further than the study.

  • 5 supported
  • 1 overstated

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

One claim overstates the study. Five of six check out.

  • 5 supported
  • 1 overstated
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedThe findings, published Aug. 27 in JAMA Network Open, suggest that a comprehensive approach to putting existing infection prevention evidence into everyday practice can substantially reduce infections among hospitalized patients.View evidenceHide evidence

As statedsubstantially reduce infections

Why this verdict

The profile supports that infection outcomes declined substantially and that the program focused on implementation of MRSA prevention practices. However, saying the findings suggest a comprehensive approach 'can substantially reduce infections' leans toward a causal effectiveness claim. The paper profile describes a pre–post, nonrandomized QI evaluation without a concurrent control group, so causal attribution is limited even though the claim is hedged. The journal/date publication detail is not verifiable from the supplied abstract profile.

1

Study evidence

Primary outcome—laboratory-identified MRSA hospital-onset bacteremia (HOB) rates decreased between baseline and the end of the program.−2.3 events per 10,000 patient-days (95% CI, −2.8 to −1.9); −65% (95% CI, −73% to −58%); P < .001

“This quality improvement study evaluates the Agency for Healthcare Research and Quality's Safety Program for MRSA Prevention”
2

Study evidence

Hospital-onset clinical cultures growing MRSA (first positive on hospital day 4 or later) decreased between baseline and end-of-program.-5.6 events per 10,000 patient-days (95% CI, -7.8 to -3.3); relative change -39% (95% CI, -50% to -29%); P < .001

“Secondary outcomes included hospital-onset clinical cultures growing MRSA, all-cause HOB, and central line-associated bloodstream infections.”
Claim 2 of 6SupportedA large-scale, quality improvement program developed in collaboration with Johns Hopkins Armstrong Institute for Patient Safety and Quality was associated with a 65% reduction in hospital-onset bloodstream infections caused by methicillin-resistant Staphylococcus aureus (MRSA) among participating hospital units.View evidenceHide evidence

As stated65% reduction

Why this verdict

The abstract-level profile supports the core headline claim that participation in the AHRQ Safety Program for MRSA Prevention was associated with a 65% reduction in laboratory-identified MRSA hospital-onset bacteremia among participating ICU and non-ICU units. The association framing is appropriate for the pre–post QI design. The Johns Hopkins Armstrong Institute collaboration detail is not independently verified in the supplied abstract profile, but the scientific effect claim is supported.

1

Study evidence

Primary outcome—laboratory-identified MRSA hospital-onset bacteremia (HOB) rates decreased between baseline and the end of the program.−2.3 events per 10,000 patient-days (95% CI, −2.8 to −1.9); −65% (95% CI, −73% to −58%); P < .001

“This quality improvement study evaluates the Agency for Healthcare Research and Quality's Safety Program for MRSA Prevention”
2

Study evidence

The program provided 22 webinars and durable educational content focused on CHG bathing, nasal MRSA decolonization, environmental disinfection, and interventions to prevent person-based MRSA transmission and device-related infections; webinars targeted nurses, infection preventionists, physicians, nursing assistants, and environmental services personnel.

“The program provided 22 webinars and durable educational content”
Claim 3 of 6SupportedThe Agency for Healthcare Research and Quality (AHRQ) Safety Program for MRSA Prevention was implemented in 106 intensive care units and 87 non-ICUs at 94 hospitals across the United States.View evidenceHide evidence

As stated106 ICUs, 87 non-ICUs, 94 hospitals

Why this verdict

The profile reports that 193 units from 94 hospitals completed the program, specifically 106 ICUs and 87 non-ICUs, matching the story’s counts.

1

Study evidence

The program provided 22 webinars and durable educational content focused on CHG bathing, nasal MRSA decolonization, environmental disinfection, and interventions to prevent person-based MRSA transmission and device-related infections; webinars targeted nurses, infection preventionists, physicians, nursing assistants, and environmental services personnel.

“The program provided 22 webinars and durable educational content”
Claim 4 of 6SupportedThe 18-month program centered on helping health care teams consistently implement a comprehensive set of infection prevention strategies targeting MRSA transmission and infection, including hand hygiene, environmental cleaning, device-associated infection prevention, chlorhexidine bathing and nasal decolonization.View evidenceHide evidence

As stated18-month program

Why this verdict

The profile supports the 18-month April 2022–September 2023 implementation context and describes webinars and durable educational content focused on chlorhexidine bathing, nasal MRSA decolonization, environmental disinfection, prevention of person-based transmission, and device-related infection prevention. The profile does not separately list hand hygiene in the abstract-level summary, but the overall description of program focus and implementation support is consistent with the paper profile.

1

Study evidence

The program provided 22 webinars and durable educational content focused on CHG bathing, nasal MRSA decolonization, environmental disinfection, and interventions to prevent person-based MRSA transmission and device-related infections; webinars targeted nurses, infection preventionists, physicians, nursing assistants, and environmental services personnel.

“The program provided 22 webinars and durable educational content”
Claim 5 of 6SupportedResearchers compared infection rates during the 18-month implementation period with rates during the 12 months before the program began and found a 39% reduction in MRSA-positive clinical cultures collected later during hospitalization, a 37% reduction in bloodstream infections from all causes, and a 31% reduction in central line-associated bloodstream infections.View evidenceHide evidence

As stated39% reduction, 37% reduction, 31% reduction

Why this verdict

The profile supports the pre–post comparison against the prior 12-month baseline and the reported secondary outcome reductions: MRSA-positive clinical cultures from hospital day 4 or later decreased 39%, all-cause hospital-onset bacteremia decreased 37%, and CLABSI decreased 31%.

1

Study evidence

Primary outcome—laboratory-identified MRSA hospital-onset bacteremia (HOB) rates decreased between baseline and the end of the program.−2.3 events per 10,000 patient-days (95% CI, −2.8 to −1.9); −65% (95% CI, −73% to −58%); P < .001

“This quality improvement study evaluates the Agency for Healthcare Research and Quality's Safety Program for MRSA Prevention”
2

Study evidence

Hospital-onset clinical cultures growing MRSA (first positive on hospital day 4 or later) decreased between baseline and end-of-program.-5.6 events per 10,000 patient-days (95% CI, -7.8 to -3.3); relative change -39% (95% CI, -50% to -29%); P < .001

“Secondary outcomes included hospital-onset clinical cultures growing MRSA, all-cause HOB, and central line-associated bloodstream infections.”
Claim 6 of 6SupportedThe article says the resulting AHRQ MRSA Prevention Toolkit is publicly available for hospitals to use or adapt.View evidenceHide evidence

Why this verdict

The profile states that program materials are publicly available and may be used by ICUs and non-ICUs to support MRSA prevention efforts. The specific 'toolkit' label is not elaborated in the abstract profile, but the public-availability claim is supported.

1

Study evidence

The program provided 22 webinars and durable educational content focused on CHG bathing, nasal MRSA decolonization, environmental disinfection, and interventions to prevent person-based MRSA transmission and device-related infections; webinars targeted nurses, infection preventionists, physicians, nursing assistants, and environmental services personnel.

“The program provided 22 webinars and durable educational content”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Generalizability limitation: participating units were volunteer hospital units, which may limit representativeness of all US acute-care hospital units.

    The supplied story caveats do not mention volunteer participation or the resulting limits on generalizability.

    From Pre–post quality improvement program evaluation; Pre–post quality improvement program evaluation; Descriptive implementa

  • Measurement/confounding limitation: aggregate surveillance-based infection metrics may be affected by concurrent infection-control initiatives, secular trends, changes in testing, reporting, surveillance definitions, or case mix.

    The story’s caveats do not mention these possible sources of temporal confounding or measurement bias.

    From Pre–post quality improvement program evaluation; Pre–post quality improvement program evaluation

7 things the story did carry across
  • Primary finding: participation in the AHRQ Safety Program for MRSA Prevention was associated with a 65% reduction in laboratory-identified MRSA hospital-onset bacteremia compared with the prior baseline period.
  • Secondary findings: hospital-onset MRSA clinical cultures, all-cause hospital-onset bacteremia, and CLABSI all declined significantly during the project period compared with baseline.
  • Study design: the evidence comes from a pre–post quality-improvement evaluation comparing project-period outcomes with the previous 12 months of baseline data.
  • Key causal limitation: the study lacked randomization and a concurrent control group, limiting attribution of observed reductions to the program alone.
  • Implementation context: the program included educational webinars and durable materials focused on CHG bathing, nasal MRSA decolonization, environmental disinfection, person-based transmission prevention, and device-related infection prevention.
  • Program/sample description: 193 units from 94 hospitals completed the program, including 106 ICUs and 87 non-ICUs.
  • Public availability: program materials are publicly available for ICUs and non-ICUs to support MRSA prevention efforts.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEvaluate whether participation in the AHRQ Safety Program for MRSA Prevention (educational QI program) is associated with reduced hospital-onset MRSA bacteremia rates in participating acute-care hospital units compared with the prior 12-month baseline.Pre–post quality improvement program evaluationExpand

In plain English

Quality-improvement evaluation of the AHRQ Safety Program for MRSA Prevention implemented in volunteer US acute-care hospital units (106 ICUs and 87 non-ICUs from 94 hospitals) from April 2022 to September 2023, compared with the prior 12-month baseline. The program (22 webinars and durable educational content focused on chlorhexidine bathing, nasal decolonization, environmental disinfection, and transmission/device-related prevention) was associated with large, statistically significant reductions in the primary outcome—laboratory-identified MRSA hospital-onset bacteremia (HOB)—and in several secondary infection metrics.

Key findings

  • Primary outcome—laboratory-identified MRSA hospital-onset bacteremia (HOB) rates decreased between baseline and the end of the program.−2.3 events per 10,000 patient-days (95% CI, −2.8 to −1.9); −65% (95% CI, −73% to −58%); P < .001
  • Hospital-onset clinical cultures growing MRSA from hospital day 4 or later decreased during the project period.−5.6 events per 10,000 patient-days (95% CI, −7.8 to −3.3); −39% (95% CI, −50% to −29%); P < .001
“This quality improvement study evaluates the Agency for Healthcare Research and Quality's Safety Program for MRSA Prevention”
What this piece can’t prove
  • Study used a pre–post comparison (project period vs prior 12-month baseline) without randomized or concurrent control groups.
  • Participating units were volunteer hospital units, potentially limiting generalizability.
  • Aggregate, surveillance-based infection metrics may be affected by concurrent infection-control initiatives, changes in testing or reporting, or temporal trends not controlled for in the design.
2secondary dataAssess whether the program is associated with improvements in secondary infection outcomes (hospital-onset clinical cultures growing MRSA, all-cause hospital-onset bacteremia, and central line–associated bloodstream infections) compared with baseline.Pre–post quality improvement program evaluationExpand

In plain English

Pre–post evaluation of the AHRQ Safety Program for MRSA Prevention in 193 hospital units (106 ICUs, 87 non-ICUs) compared baseline (previous 12 months) to end-of-program rates for secondary infection outcomes. Reported outcome measures were rates of hospital-onset clinical cultures growing MRSA (hospital day ≥4), all-cause hospital-onset bacteremia (HOB), and central line–associated bloodstream infections (CLABSI). All three secondary outcomes showed statistically significant reductions in absolute and relative rates (P < .001 for each comparison).

Key findings

  • Hospital-onset clinical cultures growing MRSA (first positive on hospital day 4 or later) decreased between baseline and end-of-program.-5.6 events per 10,000 patient-days (95% CI, -7.8 to -3.3); relative change -39% (95% CI, -50% to -29%); P < .001
  • All-cause hospital-onset bacteremia (HOB) decreased between baseline and end-of-program.-10.5 events per 10,000 patient-days (95% CI, -13.8 to -7.1); relative change -37% (95% CI, -45% to -30%); P < .001
“Secondary outcomes included hospital-onset clinical cultures growing MRSA, all-cause HOB, and central line-associated bloodstream infections.”
What this piece can’t prove
  • Pre–post (before-after) design without a concurrent control group; cannot rule out secular trends or other contemporaneous changes.
  • Participating units were volunteer sites (193 units from 94 hospitals), which may limit generalizability.
  • Potential for changes in surveillance, testing, or reporting practices across periods that could affect measured event rates.

1 further detail could not be confirmed from the summary.

3secondary dataDescribe the participating units/hospitals and the program’s implementation context (ICU vs non-ICU participation; hospital teaching status; program content focus areas).Descriptive implementation/exposure reportingExpand

In plain English

Descriptive account of units and implementation context for the Agency for Healthcare Research and Quality (AHRQ) Safety Program for MRSA Prevention: 193 hospital units (106 ICUs, 87 non-ICUs) from 94 US acute care hospitals participated in a volunteer-based quality improvement program conducted April 2022–September 2023. The program delivered 22 webinars and durable educational materials targeting nurses, infection preventionists, physicians, nursing assistants, and environmental services staff, with primary focus areas of chlorhexidine (CHG) bathing, nasal MRSA decolonization, environmental disinfection, and interventions to prevent person-to-person transmission and device-related infections. Participant hospitals included academic medical centers (31 units, 33%), non-academic medical center teaching hospitals (42 units, 45%), and nonteaching community/other hospitals (21 units, 22%). Reporting is descriptive, providing implementation/exposure context rather than estimating causal effects.

Key findings

  • The program provided 22 webinars and durable educational content focused on CHG bathing, nasal MRSA decolonization, environmental disinfection, and interventions to prevent person-based MRSA transmission and device-related infections; webinars targeted nurses, infection preventionists, physicians, nursing assistants, and environmental services personnel.
  • One hundred ninety-three hospital units completed the program (106 ICUs and 87 non-ICUs) from 94 hospitals; participating hospital units were reported as 31 (33%) academic medical centers, 42 (45%) non-academic medical center teaching hospitals, and 21 (22%) nonteaching community or other hospitals.
“The program provided 22 webinars and durable educational content”
What this piece can’t prove
  • Participating units were volunteers, which may limit generalizability to all US acute care hospital units.
  • This unit reports descriptive context only and does not present causal effect estimates for program impact.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

CandidateOpen access

Hospital-onset methicillin-resistant Staphylococcus aureus bloodstream infections within tertiary and community hospitals and implications for prevention.

Infection Control and Hospital Epidemiology · 2026 · PubMed, Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Reduction of Hospital-Onset MRSA Bloodstream Infections Through Early Identification and Intervention of High-Risk Patient Populations.

American Journal of Infection Control · 2025 · Crossref

Source (opens in a new tab)
Candidate

P4.19 Preventing Methicillin Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI) in Adult Intensive Care Units (ICU)

Journal of Hospital Infection · 2006 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.